These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 33149182)
1. A prospective cohort study on effects of gemigliptin on cardiovascular outcomes in patients with type 2 diabetes (OPTIMUS study). Kim EH; Kim SS; Kim DJ; Choi YS; Lee CW; Ku BJ; Cha KS; Song KH; Kim DK; Kim IJ Sci Rep; 2020 Nov; 10(1):19033. PubMed ID: 33149182 [TBL] [Abstract][Full Text] [Related]
2. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events. Ferdinand KC; Botros FT; Atisso CM; Sager PT Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057 [TBL] [Abstract][Full Text] [Related]
3. A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus. Yang SJ; Min KW; Gupta SK; Park JY; K Shivane V; Agarwal PK; Kim DM; Kim YE; Baik SH Diabetes Metab J; 2021 Jul; 45(4):606-612. PubMed ID: 33081425 [TBL] [Abstract][Full Text] [Related]
4. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes. Yang SJ; Min KW; Gupta SK; Park JY; Shivane VK; Pitale SU; Agarwal PK; Sosale A; Gandhi P; Dharmalingam M; Mohan V; Mahesh U; Kim DM; Kim YS; Kim JA; Kim PK; Baik SH Diabetes Obes Metab; 2013 May; 15(5):410-6. PubMed ID: 23170990 [TBL] [Abstract][Full Text] [Related]
5. Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry. Kim SH; Lee SH; Yim HJ Arch Pharm Res; 2013 Oct; 36(10):1185-8. PubMed ID: 23771499 [TBL] [Abstract][Full Text] [Related]
6. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study. Han SY; Yoon SA; Han BG; Kim SG; Jo YI; Jeong KH; Oh KH; Park HC; Park SH; Kang SW; Na KR; Kang SW; Kim NH; Jang Y; Kim B; Shin S; Cha DR Diabetes Obes Metab; 2018 Feb; 20(2):292-300. PubMed ID: 28719008 [TBL] [Abstract][Full Text] [Related]
8. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. Holden SE; Jenkins-Jones S; Morgan CL; Schernthaner G; Currie CJ Diabetes Obes Metab; 2015 Apr; 17(4):350-62. PubMed ID: 25399739 [TBL] [Abstract][Full Text] [Related]
9. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C; Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545 [TBL] [Abstract][Full Text] [Related]
10. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Hernandez AF; Green JB; Janmohamed S; D'Agostino RB; Granger CB; Jones NP; Leiter LA; Rosenberg AE; Sigmon KN; Somerville MC; Thorpe KM; McMurray JJV; Del Prato S; Lancet; 2018 Oct; 392(10157):1519-1529. PubMed ID: 30291013 [TBL] [Abstract][Full Text] [Related]
11. Effect of adding GLP-1RA on mortality, cardiovascular events, and metabolic outcomes among insulin-treated patients with type 2 diabetes: A large retrospective UK cohort study. Anyanwagu U; Mamza J; Donnelly R; Idris I Am Heart J; 2018 Feb; 196():18-27. PubMed ID: 29421011 [TBL] [Abstract][Full Text] [Related]
12. The effect of radial pulse spectrum on the risk of major adverse cardiovascular events in patients with type 2 diabetes. Chang CW; Liao KM; Chang YT; Wang SH; Chen YC; Wang GC J Diabetes Complications; 2019 Feb; 33(2):160-164. PubMed ID: 30381150 [TBL] [Abstract][Full Text] [Related]
13. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke. Verma S; Poulter NR; Bhatt DL; Bain SC; Buse JB; Leiter LA; Nauck MA; Pratley RE; Zinman B; Ørsted DD; Monk Fries T; Rasmussen S; Marso SP Circulation; 2018 Dec; 138(25):2884-2894. PubMed ID: 30566004 [TBL] [Abstract][Full Text] [Related]
14. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). Wilcox R; Kupfer S; Erdmann E; Am Heart J; 2008 Apr; 155(4):712-7. PubMed ID: 18371481 [TBL] [Abstract][Full Text] [Related]
15. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects. Park SI; Lee H; Oh J; Lim KS; Jang IJ; Kim JA; Jung JH; Yu KS Drug Des Devel Ther; 2015; 9():729-36. PubMed ID: 25678778 [TBL] [Abstract][Full Text] [Related]
16. Linagliptin in patients with type 2 diabetes and cardiovascular and/or renal disease: results from a cardiovascular and renal outcomes trial. Guthrie R Postgrad Med; 2020 May; 132(4):314-319. PubMed ID: 32164494 [TBL] [Abstract][Full Text] [Related]
18. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Vaccaro O; Masulli M; Nicolucci A; Bonora E; Del Prato S; Maggioni AP; Rivellese AA; Squatrito S; Giorda CB; Sesti G; Mocarelli P; Lucisano G; Sacco M; Signorini S; Cappellini F; Perriello G; Babini AC; Lapolla A; Gregori G; Giordano C; Corsi L; Buzzetti R; Clemente G; Di Cianni G; Iannarelli R; Cordera R; La Macchia O; Zamboni C; Scaranna C; Boemi M; Iovine C; Lauro D; Leotta S; Dall'Aglio E; Cannarsa E; Tonutti L; Pugliese G; Bossi AC; Anichini R; Dotta F; Di Benedetto A; Citro G; Antenucci D; Ricci L; Giorgino F; Santini C; Gnasso A; De Cosmo S; Zavaroni D; Vedovato M; Consoli A; Calabrese M; di Bartolo P; Fornengo P; Riccardi G; ; Lancet Diabetes Endocrinol; 2017 Nov; 5(11):887-897. PubMed ID: 28917544 [TBL] [Abstract][Full Text] [Related]
19. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Zinman B; Wanner C; Lachin JM; Fitchett D; Bluhmki E; Hantel S; Mattheus M; Devins T; Johansen OE; Woerle HJ; Broedl UC; Inzucchi SE; N Engl J Med; 2015 Nov; 373(22):2117-28. PubMed ID: 26378978 [TBL] [Abstract][Full Text] [Related]
20. Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial. Verma S; Bain SC; Buse JB; Idorn T; Rasmussen S; Ørsted DD; Nauck MA JAMA Cardiol; 2019 Dec; 4(12):1214-1220. PubMed ID: 31721979 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]